Millennium Management LLC trimmed its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 16.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,177,953 shares of the company's stock after selling 993,093 shares during the period. Millennium Management LLC owned 4.94% of MaxCyte worth $20,298,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cadian Capital Management LP bought a new position in MaxCyte in the 4th quarter valued at about $26,531,000. PNC Financial Services Group Inc. bought a new stake in MaxCyte during the fourth quarter worth approximately $29,000. Salem Investment Counselors Inc. lifted its position in MaxCyte by 104.0% in the first quarter. Salem Investment Counselors Inc. now owns 56,375 shares of the company's stock worth $236,000 after purchasing an additional 28,741 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in MaxCyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company's stock valued at $83,000 after purchasing an additional 7,898 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in MaxCyte during the 1st quarter valued at $174,000. Institutional investors own 68.81% of the company's stock.
MaxCyte Price Performance
Shares of MXCT traded up $0.05 during midday trading on Friday, reaching $3.67. The stock had a trading volume of 252,597 shares, compared to its average volume of 529,193. The company has a market capitalization of $384.70 million, a P/E ratio of -10.49 and a beta of 1.39. The firm's 50 day moving average price is $4.11 and its 200-day moving average price is $4.25. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55.
MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The company had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. During the same period in the prior year, the company earned ($0.10) EPS. On average, equities analysts forecast that MaxCyte, Inc. will post -0.44 earnings per share for the current year.
Insider Buying and Selling
In other news, EVP Thomas M. Ross sold 13,531 shares of the business's stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $4.03, for a total transaction of $54,529.93. Following the sale, the executive vice president now directly owns 25,000 shares of the company's stock, valued at $100,750. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Thomas M. Ross sold 13,531 shares of the business's stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $4.03, for a total transaction of $54,529.93. Following the sale, the executive vice president now owns 25,000 shares in the company, valued at $100,750. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas M. Ross sold 15,476 shares of MaxCyte stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $4.54, for a total transaction of $70,261.04. Following the transaction, the executive vice president now owns 25,000 shares in the company, valued at approximately $113,500. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,381 shares of company stock worth $361,678. Corporate insiders own 3.00% of the company's stock.
MaxCyte Company Profile
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
